Actinium Pharma: Eyes two-month high after positive cancer drug data

Actinium Pharmaceuticals

04/06/2019 14:12

** Biopharmaceutical company's  ATNM.A  shares up 14.7% at
$0.35 in premarket trading, their highest in nearly two months
    ** Co presented new data from a late-stage study for its
drug, Iomab-B's effect in patients with active, relapsed or
refractory acute myeloid leukemia, a type of cancer of the blood
and bone marrow  urn:newsml:reuters.com:*:nPnc6rx6za
    ** The drug had a significant anti-leukemic effect, and was
able to effectively and rapidly reduce peripheral blasts, the
company said, adding it was highly encouraged by the results
    ** Up to close on Friday, co's shares had fallen ~25% over
the last one year

 (Reporting By Aparajita Saxena in Bengaluru)
 ((Aparajita.Saxena@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806 749 8901; Reuters Messaging:
aparajita.saxena.thomsonreuters.com@reuters.net))